Dose Reference Table

Pre-calculated for a 2.4mg vial + 0.5ml BAC water = 4,800 mcg/ml concentration. Using a 100-unit (1ml) insulin syringe.

Dose Inject Volume (ml) Syringe Units
300mcg 0.063 ml 6.3 units
600mcg 0.125 ml 12.5 units
1200mcg 0.250 ml 25 units
2400mcg (2.4mg) 0.500 ml 50 units

About Cagrilintide

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It plays a role in satiety signaling, gastric emptying, and glucagon suppression. Cagrilintide is designed for once-weekly subcutaneous administration due to modifications that extend its half-life to approximately 7 days.

The most exciting research on cagrilintide involves its combination with semaglutide, known as "CagriSema." This combination showed remarkable weight loss results in clinical trials — potentially superior to either agent alone — by targeting both GLP-1 and amylin receptor pathways simultaneously.

Cagrilintide is typically supplied in 2.4mg vials, mirroring the maximum weekly dose studied in clinical trials. Reconstituting with 0.5ml of bacteriostatic water gives a concentration of 4,800 mcg/ml. The full 2.4mg dose requires 0.5ml = 50 units on a 100-unit insulin syringe.

As an investigational compound, cagrilintide is studied for its effects on body weight, glycemic control, and metabolic health, typically in combination with GLP-1 receptor agonists.

Frequently Asked Questions

Clinical studies have evaluated cagrilintide at doses up to 2.4mg weekly. For a 2.4mg vial + 0.5ml BAC water (4800 mcg/ml), the full dose = 0.5ml = 50 units.
CagriSema is the investigational combination of cagrilintide (amylin analogue) + semaglutide (GLP-1 agonist). Clinical trials have shown this combination may produce greater weight loss than either drug alone.
Add 0.5ml of bacteriostatic water to the 2.4mg cagrilintide vial. This gives 4800 mcg/ml. Inject slowly along the glass wall, gently swirl until dissolved. Store at 2–8°C.
Cagrilintide has a half-life of approximately 7 days, supporting once-weekly dosing. This matches the weekly dosing schedule of semaglutide when used in the CagriSema combination.
Yes — the CagriSema combination (cagrilintide + semaglutide) is being actively studied in clinical trials and has shown promising weight loss results. Research protocols typically administer each as a separate injection or co-formulated.